Medicines List

Description

Amarhyton is a Class IC antiarrhythmic agent used in the treatment of severe symptomatic life-threatening ventricular arrhythmias and supraventricular arrhythmias.

Indications

Amarhyton is used for treatment of:
– AV nodal reciprocating tachycardia; arrhythmias associated with Wolff-Parkinson-White Syndrome and similar conditions with accessory pathways, when other treatment has been ineffective;
– Severe symptomatic and life-threatening paroxysmal ventricular arrhythmia which has failed to respond to other forms of therapy. Also where other treatments have not been tolerated;
– Paroxysmal atrial arrhythmias (atrial fibrillation, atrial flutter and atrial tachycardia) in patients with disabling symptoms after conversion provided that there is definite need for treatment on the basis of severity of clinical symptoms, when other treatment has been ineffective. Structural heart disease and/or impaired left ventricular function should be excluded because of the increased risk for pro-arrhythmic effects.

Subject to medical prescription.

Concentration and pharmaceutical form: 50 mg; 100 mg; 150 mg prolonged-release capsules, hard

Description

Pizona contains pioglitazone.
Pizona helps controlling the level of sugar in your blood when you have type 2 diabetes by helping your body make better use of the insulin it produces.

Indications

Pioglitazone is indicated for treatment of type 2 diabetes mellitus.

as monotherapy:
– in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance.

as dual oral therapyin combination with:
– metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;
– a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea.

as triple oral therapyin combination with:
– metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.

Subject to medical prescription.

Concentration and pharmaceutical form: 15 mg, 30 mg, 45 mg tablets

Description

Capeda belongs to the group of medicines called “cytostatic agents”, which stop the growth of cancer cells. Capeda Tablets contain 150mg or 500mg capecitabine, which itself is not a cytostatic agent. Only after being absorbed by the body is it changed into an active anti-cancer agent (more in tumour tissue than in normal tissue).

Indications

Capeda is indicated for the adjuvant treatment of patients following surgery of stage III (Dukes’ stage C) colon cancer (see section 5.1 of SPC).

Capeda is indicated for the treatment of metastatic colorectal cancer (see section 5.1 of SPC).

Capeda is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen (see section 5.1 of SPC).

Capeda in combination with docetaxel (see section 5.1) is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Capecitabine is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.

Subject to medical prescription

Pharmaceutical form: 150 mg film-coated tablets x 60 tablets

NHIF code:

ICD:C50; C16; C18; C19; C20

Pharmaceutical form: 500 mg film-coated tablets x 120 tablets

NHIF code:

ICD:C50; C16; C18; C19; C20

АТС code: L01BC06

Description

Indications

Hronileucem is indicated for the treatment of

• paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.

• paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.

•adult  with Ph+ CML in blast crisis.

• adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.

• adult patients with relapsed or refractory Ph+ ALL as monotherapy.

• adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.

• adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement.

The effect of Hronileucem on the outcome of bone marrow transplantation has not been determined.

Hronileucem is indicated for

• the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).

• the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment.

• the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.

In adult and paediatric patients, the effectiveness of Hronileucem is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic GIST and DFSP and on recurrence-free survival in adjuvant GIST. The experience with Hronileucem in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1 of SPC). Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases.

Subject to medical prescription

Pharmaceutical form: 100 mg capsules, hard x 120 capsules

NHIF code: ICD:C18; C19; C20; C92.1

Pharmaceutical form: 400 mg capsules, hard x 30 capsules

NHIF code: ICD:C18; C19; C20; C92.1

АТС: L01XЕ01